Product Name: PKCb-pS661

Product Number: AB-PK765

Size:	25 µg		Price:	89.00
			$US

Target Full Name: Protein-serine kinase C beta 1

Target Alias: Kinase PKC-beta; KPCB; MGC41878; PKC II; PKC-B; PKC-beta; PKC-II; PRKCB; PRKCB1; PRKCB2; Protein kinase C, beta type

Product Type Specific: Protein kinase phosphosite-specific antibody

Antibody Code: PK765

Antibody Target Type: Phosphosite-specific

Antibody Phosphosite: S661

Protein UniProt: P05771

Protein SigNET: P05771

Antibody Type: Polyclonal

Antibody Host Species: Rabbit

Antibody Immunogen Source: Human PKCb (PRKCB1) sequence peptide Cat. No.: PE-04AOV99

Antibody Immunogen Sequence: AGF(pS)YTN(bA)C

Antibody Immunogen Description: Corresponds to amino acid residues A658 to N664; In Pkinase_C domain near C-terminus of the kinase

Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.This antibody was also subject to negative purification over phosphotyrosine-agarose.

Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.

Antibody Concentration: 1 mg/ml

Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol

Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.

Product Use: Western blotting | Antibody microarray

Antibody Dilution Recommended: 2 µg/ml for immunoblotting

Antibody Potency: Strong immunoreactivity with immunogen peptide on dot blots.

Antibody Species Reactivity: Human

Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 75-85 kDa.

Scientific Background: PKCb (PRKCB, PKC-beta) is a protein-serine/threonine kinase in the classical protein kinase C family. It is calcium activated, and dependent on acidic phospholipids (e.g. phosphatidylserine) and diacylglycerol for full phosphotransferase activity. PKCb can bind 3 calcium ions for each subunit. Phosphorylation of T635 and T642 is critical for kinase activity. Phosphorylation of S661 inhibits membrane binding and causes release into cytoplasm. PKCbI is highly related to PKCbII. Unlike the mature PKCb II mRNA and protein, which rapidly increase following acute insulin treatment, the PKCbI mRNA and protein levels remain unchanged. Stable overexpression of PKCbII, but not PKCbI, leads to insulin-stimulated glucose uptake into cells. PKCb can mediate B-cell receptor signalling, and apoptosis induced by oxidative stress. PKCb can regulate oxidative stress inducing apoptosis, signalosome, B-cell activation, transcription regulation dependent on androgen receptor signalling, endothelial cell proliferation, and insulin secretion. PKCb can phosphorylate CARD11/CARMA1 at S559, S644, and S652. Upon stimulation of B cells and mast cells, Syk regulates Btk, and Btk selectively regulates enzymatic activity of PKCbI. Specific regulation of PKCbI by Btk is consistent with the selective association of Btk with PKCbI. PKCb has been linked with the development of diabetic nephropathy, colorectal adenocarcinomas and glioblastoma multiforme. PKCb may be an oncoprotein (OP), although it may also be a tumour suppressor protein, since it is actually down-regulated by phorbol esters and other tumour promoters. A higher Gleason Score significantly associated with increased PKCb expression in prostate cancer.

Figure 1. Dot blotting PKCb-pS661 antibody with recombinant purified proteins.

Figure 2. Epitope mapping of PKCb-pS661 antibody with similar phosphopeptides on dot blots.

Figure 3. Identification of phosphosites related to PKCb-pS661.